Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10428476" target="_blank" >RIV/00216208:11110/21:10428476 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/21:10428476

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=j0nCJ-FEjM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=j0nCJ-FEjM</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/NXI.0000000000000979" target="_blank" >10.1212/NXI.0000000000000979</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Popis výsledku v původním jazyce

Objective: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remitting multiple sclerosis (RRMS), to describe the association between BVL and clinical measures, and to investigate an effect of treatment escalation on the rate of BVL. Methods: Together, 1903 patients predominantly with RRMS from the Avonex-Steroids-Azathioprine cohort (N = 166), the study of early IFN-β1a treatment cohort (N = 180), and the quantitative MRI cohort (N = 1,557) with &gt;=2 MRI scans and &gt;=1-year of follow-up were included. Brain MRI scans (N = 7,203) were performed using a single 1.5-T machine. Relationships between age or disease duration and global and tissue-specific BVL rates were analyzed using mixed models. Results: Age was not associated with the rate of BVL (β = -0.003; Cohen f2 = 0.0005; adjusted p = 0.39). Although disease duration was associated with the rate of BVL, its effect on the BVL rate was minimal (β = -0.012; Cohen f2 = 0.004; adjusted p = 4 x 10-5). Analysis of association between tissue-specific brain volume changes and age (β = -0.019 to -0.011; adjusted p = 0.028-1.00) or disease duration (β = -0.028 to -0.008; adjusted p = 0.16-0.96) confirmed these results. Although increase in the relapse rate (β = 0.10; adjusted p = 9 x 10-9), Expanded Disability Status Scale (EDSS; β = 0.17; adjusted p = 8 x 10-5), and EDSS change (β = 0.15; adjusted p = 2 x 10-5) were associated with accelerated rate of BVL, their effect on the rate of BVL was minimal (all Cohen f2 &lt;= 0.007). In 94 patients who escalated therapy, the rate of BVL decreased following treatment escalation by 0.29% (β = -0.29; Cohen f2 = 0.133; p = 5.5 x 10-8). Conclusions: The rate of BVL is relatively stable throughout the course of RRMS. The accelerated BVL is weakly associated with concurrent higher disease activity, and timely escalation to high-efficacy immunotherapy helps decrease the rate of BVL.

Název v anglickém jazyce

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis

Popis výsledku anglicky

Objective: To describe the dynamics of brain volume loss (BVL) at different stages of relapsing-remitting multiple sclerosis (RRMS), to describe the association between BVL and clinical measures, and to investigate an effect of treatment escalation on the rate of BVL. Methods: Together, 1903 patients predominantly with RRMS from the Avonex-Steroids-Azathioprine cohort (N = 166), the study of early IFN-β1a treatment cohort (N = 180), and the quantitative MRI cohort (N = 1,557) with &gt;=2 MRI scans and &gt;=1-year of follow-up were included. Brain MRI scans (N = 7,203) were performed using a single 1.5-T machine. Relationships between age or disease duration and global and tissue-specific BVL rates were analyzed using mixed models. Results: Age was not associated with the rate of BVL (β = -0.003; Cohen f2 = 0.0005; adjusted p = 0.39). Although disease duration was associated with the rate of BVL, its effect on the BVL rate was minimal (β = -0.012; Cohen f2 = 0.004; adjusted p = 4 x 10-5). Analysis of association between tissue-specific brain volume changes and age (β = -0.019 to -0.011; adjusted p = 0.028-1.00) or disease duration (β = -0.028 to -0.008; adjusted p = 0.16-0.96) confirmed these results. Although increase in the relapse rate (β = 0.10; adjusted p = 9 x 10-9), Expanded Disability Status Scale (EDSS; β = 0.17; adjusted p = 8 x 10-5), and EDSS change (β = 0.15; adjusted p = 2 x 10-5) were associated with accelerated rate of BVL, their effect on the rate of BVL was minimal (all Cohen f2 &lt;= 0.007). In 94 patients who escalated therapy, the rate of BVL decreased following treatment escalation by 0.29% (β = -0.29; Cohen f2 = 0.133; p = 5.5 x 10-8). Conclusions: The rate of BVL is relatively stable throughout the course of RRMS. The accelerated BVL is weakly associated with concurrent higher disease activity, and timely escalation to high-efficacy immunotherapy helps decrease the rate of BVL.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NV18-04-00168" target="_blank" >NV18-04-00168: Kvantitativní zobrazení míchy pomocí magnetické rezonance, korelace s klinickým stavem a hladinou neurofilament u pacientů s roztroušenou sklerózou</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurology: Neuroimmunology &amp; Neuroinflammation

ISSN

2332-7812

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

e979

Kód UT WoS článku

000658833000009

EID výsledku v databázi Scopus

2-s2.0-85103146211